
Adding the investigational, oral drug teriflunomide to glatiramer acetate (GA, Copaxone) in patients with relapsing multiple sclerosis substantially decreased the MRI lesion burden, although the effect on relapse rates was less clear, a researcher said here.
In a 48-week, phase II trial, patients receiving 7 mg/day of teriflunomide in addition to GA had only about one-third the average number of T1-gadolinium-enhancing lesions seen in patients taking placebo plus GA (P=0.03), said Mark Freedman, MD, of the University of Ottawa.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767